Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials

Find Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials Near You

Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterized by the degeneration of motor neurons leading to progressive paralysis and death within 3 to 5 years after diagnosis. To date, no key mechanism had been identified. Our associated laboratory has identified the P2X4 purinergic pathway that appears to be involved in the pathogenesis of ALS. Our goal is to verify these results at the human level in order to have a proof of concept of P2X4's role as a biomarker of the disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• For ALS group: Person presenting a probable or confirmed diagnosis of ALS according to the criteria of EI Escorial.

• Adult.

• Person affiliated or beneficiary of a social security scheme.

• Free, informed and written consent signed by the participant or by a third person (in case of physical incapacity of the participant), after information on the study.

Locations
Other Locations
France
Hôpital Pellegrin
RECRUITING
Bordeaux
Contact Information
Primary
Gwendal Le Masson, Pr
gwendal.le-masson@chu-bordeaux.fr
05 57 82 13 70
Backup
Claire Fremy
claire.fremy@chu-bordeaux.fr
Time Frame
Start Date: 2026-01-15
Estimated Completion Date: 2027-07
Participants
Target number of participants: 50
Treatments
Experimental: ALS patient
During the inclusion visit on D0, which will take place during a consultation or a hospitalization scheduled as part of the standard of care, patients will be informed about the protocol and their informed consent will be obtained.~A neurological clinical examination will be performed, the ALSFRS-R score will be evaluated, as well as respiratory functional explorations and a standard biology assessment. As part of the research, an additional blood sample will be taken.~For ALS patients, a follow-up visit will be performed at 6 months as part of their follow-up consultation at the ALS center. The same examinations as on D0 will be done.
Other: Standard : healthy subjects
During the inclusion visit on D0, which will take place during a consultation or a hospitalization scheduled as part of the standard of care. A neurological clinical examination will be performed, the ALSFRS-R score will be evaluated, as well as respiratory functional explorations and a standard biology assessment. As part of the research, an additional blood sample will be taken.~For healthy subjects, a follow-up visit will be performed at 6 months. The same examinations as on D0 will be done.
Sponsors
Leads: University Hospital, Bordeaux

This content was sourced from clinicaltrials.gov